Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Traumalix Dolo
- Development stage
- Unknown
- Lead developer
- Drossapharm
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Traumalix Dolo is a topical analgesic and anti-inflammatory gel developed by Drossapharm AG for the treatment of sports-related injuries, including sprains, contusions, and strains. The active ingredient is etofenamat (5%), a small molecule non-steroidal anti-inflammatory drug (NSAID). Etofenamat works by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for the synthesis of prostaglandins that mediate pain and inflammation. The gel formulation is designed for external application, allowing the active substance to penetrate the skin and reach the underlying affected tissues. It is currently approved and marketed in Switzerland.
- Brand names
- Traumalix Dolo
- Other names
- Traumalix Dolo Gel
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on Traumalix Dolo.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Traumalix Dolo.